A Phase Ib/II Study of ATG-022 Plus Pembrolizumab With/Without Chemotherapy in Participants With Claudin (CLDN) 18.2-positive, HER2-negative, Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaUnresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Clinical trial NCT07327229 · RECRUITING

Trial details

NCT number: NCT07327229
Sponsor: Antengene Biologics Limited
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Start date: 2026-02-27
Primary completion: 2027-09-30
Enrollment: 132

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.